Actively Recruiting
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
Led by Sun Yat-sen University · Updated on 2025-11-18
524
Participants Needed
1
Research Sites
265 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, randomized, controlled, multi-center phase III clinical trial that intends to evaluate the role of early cardiovascular intervention based on impedance cardiography in patients with locally advanced non-small cell lung cancer receiving radical radiochemotherapy±immunotherapy.
CONDITIONS
Official Title
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with non-small cell lung cancer confirmed by pathology or cytology
- Assessed as locally advanced, unresectable stage III by imaging
- Planned treatment includes radical radiotherapy and chemotherapy with or without immunotherapy
- Male or female aged between 18 and 75 years
- Life expectancy of at least 12 weeks
- WHO performance status score of 0 or 1
- Organ and bone marrow function meeting specified standards including FEV1 ≥1000 ml, neutrophils ≥1.5×10^9/L, platelets ≥100×10^9/L, hemoglobin ≥90 g/L, creatinine clearance ≥50 mL/min, bilirubin ≤1.5 times upper limit of normal, and liver enzymes ≤2.5 times upper limit of normal
- Signed informed consent prior to any study procedures
- Presence of abnormal initial cardiac output index
You will not qualify if you...
- WHO performance status score of 2 to 4
- Organ function impairment including FEV1 <1000 ml, neutrophils <1.5×10^9/L, platelets <100×10^9/L, hemoglobin <90 g/L, creatinine clearance <50 mL/min, bilirubin >1.5 times upper limit of normal, liver enzymes >2.5 times upper limit of normal
- Unstable angina or myocardial infarction within the past month
- Uncontrolled arrhythmia causing symptoms or abnormal hemodynamics
- Active endocarditis
- Symptomatic severe aortic stenosis
- Uncontrolled heart failure
- Acute pulmonary embolism, pulmonary infarction, or low thrombosis formation
- Suspected or confirmed aortic dissection
- Uncontrolled bronchial asthma
- Pulmonary edema
- Fingertip blood oxygen saturation at rest ≤85%
- Acute non-cardiopulmonary diseases affecting or worsened by exercise such as infection, renal failure, or thyrotoxicosis
- Mental disorders preventing cooperation
- Patients clearly recommended for drug intervention per 2022 European Society of Cardiology Cardio-Oncology Guidelines
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
B
Bo Qiu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here